Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Banco Santander: Trading At 5x Earnings And A 35% Discount To Its TBV
11:35am, Saturday, 03'rd Dec 2022
Banco Santander generates almost 70% of its income outside of Europe. The earnings remain strong, and the bank has a shot at a full-year EPS of 0.55 EUR per share.
Press Release: Statement from Sanofi regarding: rule 2.12 of the takeover rules
06:55am, Friday, 02'nd Dec 2022 GlobeNewswire Inc.
Communiqué de presse : Annonce de Sanofi au sujet de la règle 2.12 des "takeover rules"
06:55am, Friday, 02'nd Dec 2022 GlobeNewswire Inc.
Banks are short more than $1 trillion in capital, says this analyst, who fears the shortfall will only get worse
01:37pm, Wednesday, 30'th Nov 2022 MarketWatch
If bank assets are marked to market, the U.S. sector is insolvent, according to an independent analyst.
Press Release: Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa
07:00am, Wednesday, 30'th Nov 2022 GlobeNewswire Inc.
Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa
Communiqué de presse : Acoziborole : un médicament expérimental oral et à dose unique pourrait permettre d’éliminer la maladie du sommeil en Afrique
07:00am, Wednesday, 30'th Nov 2022 GlobeNewswire Inc.
Acoziborole : un médicament expérimental oral et à dose unique pourrait permettre d’éliminer la maladie du sommeil en Afrique
Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
05:50pm, Thursday, 17'th Nov 2022 GlobeNewswire Inc.
European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
Communiqué de presse: La Commission européenne approuve Enjaymo® (sutimlimab) pour le traitement de l’anémie hémolytique de l’adulte atteint de la maladie des agglutinines froides
05:50pm, Thursday, 17'th Nov 2022 GlobeNewswire Inc.
La Commission européenne approuve Enjaymo® (sutimlimab) pour le traitement de l’anémie hémolytique de l’adulte atteint de la maladie des agglutinines froides
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2022
10:42pm, Monday, 14'th Nov 2022 GlobeNewswire Inc.
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marc
Sanofi: Information concerning the total number of voting rights and shares – October 2022
10:42pm, Monday, 14'th Nov 2022 GlobeNewswire Inc.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
China eases some travel requirements in move welcomed by markets, even as it counts 10,000 new COVID cases in a day
06:55pm, Friday, 11'th Nov 2022 MarketWatch
China counted more than 10,000 fresh COVID cases on Friday sparking further restrictions on movement, but also eased some travel requirements
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
12:00pm, Friday, 11'th Nov 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
Communiqué de presse: Le CHMP recommande l’approbation de Dupixent® (dupilumab) dans l’Union européenne pour le traitement du prurigo nodulaire
12:00pm, Friday, 11'th Nov 2022 GlobeNewswire Inc.
Le CHMP recommande l’approbation de Dupixent® (dupilumab) dans l’Union européenne pour le traitement du prurigo nodulaire
Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
03:36pm, Thursday, 10'th Nov 2022 GlobeNewswire Inc.
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
Communiqué de presse : VidPrevtyn® Beta, le vaccin de rappel nouvelle génération contre la COVID-19 de Sanofi et GSK, approuvé par la Commission européenne
03:36pm, Thursday, 10'th Nov 2022 GlobeNewswire Inc.
VidPrevtyn® Beta, le vaccin de rappel nouvelle génération contre la COVID-19 de Sanofi et GSK, approuvé par la Commission européenne
